ISIntan Nureslyna Samsudin

Intan Nureslyna Samsudin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Intan Nureslyna Samsudin has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unmeasurable Total Bilirubin in an 80-Year-Old Man

    by Najmul Aufa Mohamad Zulkipli, Yin Ye Lai, Subashini C. Thambiah, Intan Nureslyna Samsudin, Muhamad Syahmi Nazli

  • In vivo and in vitro hemolysis in cold autoimmune hemolytic anemia

    by Mohammad Faiz Bin Masri, Yin Ye Lai, Siti Sarah Binti Mustapa, Intan Nureslyna Samsudin, Subashini Chellappah Thambiah

    Introduction: Cold-reacting antibodies that bind to and trigger premature erythrocyte destruction are present in patients with cold autoimmune hemolytic anemia (cAIHA). The diagnosis of cAIHA is challenging because of the rarity of the disease, especially in patients with nonspecific features. Methods: In this case report, we discuss an unusual case of cAIHA in an older man who presented with asymptomatic hyperkalemia, highlighting the hematologic and biochemical changes associated with the disease. Results: Although hyperkalemia is expected with in vivo hemolysis because of autoantibody-mediated destruction of red blood cells, pseudohyperkalemia caused by in vitro hemolysis was also detected. The combination of actual in vivo hyperkalemia and pseudohyperkalemia resulted in a measured potassium value that was higher than the in vivo potassium concentration. Discussion: It is pertinent to consider both in vivo and in vitro hemolysis in patients with cAIHA, particularly when assessing potassium status, so that an appropriate intervention can be administered for better patient outcomes.

  • Acute Sodium Fluctuation in Altered Consciousness: A Puzzle or a Key to Diagnosis?

    by Suet Ying Woon, Subashini C. Thambiah, Hanisah Abdul Hamid, Intan Nureslyna Samsudin, Yin Ye Lai

  • Milky ascitic fluid in a newborn

    by Jannaltul A Azmi, Subashini C Thambiah, Yee L Lee, Siti Y Zahari Sham, Hanisah Abdul Hamid, Intan N Samsudin

  • Open Access

    Different reference ranges affect the prevalence of osteoporosis and osteopenia in an urban adult Malaysian population

    by Swan Sim Yeap, Subashini C. Thambiah, Intan Nureslyna Samsudin, Geeta Appannah, Nurunnaim Zainuddin, Safarina Mohamad-Ismuddin, Nasrin Shahifar, Salmiah Md-Said, Siti Yazmin Zahari-Sham, Subapriya Suppiah, et al.


  • Open Access

    Persistent Hyponatremia in an Elderly Patient

    by Yin Ye Lai, Intan Nureslyna Samsudin, Normaizuwana Mohamed Mokhtar, Subashini C. Thambiah


  • A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort

    by Subashini C. Thambiah, Meor Fairuz Rizal Meor Anuar Shuhaili, Boon How Chew, Intan Nureslyna Samsudin, Hejar Abdul Rahman, Johnson Stanslas, Shariful Hasan, Zalinah Ahmad

    Introduction: Statin, the first-line treatment for dyslipidaemia, may have suboptimal adherence due to its associated muscle adverse events. This data however, remains limited. Aim: To determine the association of serum creatine kinase(CK) and SLCO1B1 rs4363657 polymorphism with statin-associated muscle adverse events(SAMAE) among dyslipidaemia participants. Methods: This was a prospective cohort study at government health clinics involving newly diagnosed adults with dyslipidaemia. SAMAE were recorded based on the patient’s complaint after a month on statin. CK was taken at baseline and follow-up. Genetic profiling was performed for SLCO1B1 rs4363657 polymorphism. Results: Among 118 participants, majority were Malay(72%) males(61%) with a mean age of 49 ± 12.2 years old and prescribed lovastatin(61.9). There was a significant association between statin types(lovastatin and simvastatin) and SAMAE(p = 0.0327); no significant association noted between CK and SAMAE(p = 0.5637). The SLCO1B1 rs4363657 polymorphism was significantly associated SAMAE(p < 0.0001). Conclusions: In this first pilot study of a multiethnic Malaysian population, the incidence of SAMAE was 18.6%. SAMAE were significantly higher in subjects on lovastatin compared to simvastatin. SLCO1B1 rs4363657 polymorphism was a significant risk factor for SAMAE.


  • The challenge of improving the diagnostic yield from metanephrine testing in suspected phaeochromocytoma and paraganglioma

    by Intan Nureslyna Samsudin, Michael M Page, Kirsten Hoad, Paul Chubb, Melissa Gillett, Paul Glendenning, Samuel Vasikaran

    Background: Plasma free metanephrines (PFM) or urinary fractionated metanephrines (UFM) are the preferred biochemical tests for the diagnosis of phaeochromocytoma and paraganglioma (PPGL). Borderline increased results should be followed up to either exclude or confirm diagnosis. Methods: We extracted all PFM and UFM results reported by our laboratory over a 6-month period from the laboratory information system. We categorised patients with borderline increased results according to whether follow-up testing had been performed as suggested in the initial laboratory report. Questionnaires were then sent to all requesting doctors and medical notes reviewed where available. Results: Two hundred and four patients with borderline increased PFM or UFM were identified. Sixty-five (38.5%) of 169 patients with borderline increased PFM had a repeat test out of which 36 were normal and 29 did not normalize. Of 35 patients with borderline increased UFM, 17 (48.6%) had subsequent PFM measurement out of which 15 were normal. Questionnaires were returned for 106 (52%) of patients. Of these, the most frequent indication for testing was hypertension (n=50); 15 patients had an incidental adrenal mass and two of these patients were diagnosed with a phaeochromocytoma. Conclusion: Only thirty-eight percent of patients with borderline increased PFM had a repeat PFM measurement. This was not significantly higher when compared to the 28% in a previous audit that we reported in 2010 (P=0.10). Forty nine percent of patients with a borderline increased UFM had a repeat UFM or PFM measurement. There remains a substantial possibility of missed detection of PPGL.


  • Open Access

    Trends in post osteoporotic hip fracture care from 2010 to 2014 in a private hospital in Malaysia

    by Swan Sim Yeap, M.F.R. Nur Fazirah, C. Nur Aisyah, Siti Yazmin Zahari Sham, Intan Nureslyna Samsudin, Subashini C. Thambiah, Fen Lee Hew, Boon Ping Lim, Yew Siong Siow, Siew Pheng Chan


    • 4 November 2016
      • Vol. 29  (3) , 136-140

    Pre-transplantation serum ferritin as a prognostic marker in allogeneic haemopoietic stem cell transplant patients in a tertiary care hospital in Malaysia.

    by Subashini C Thambiah, Elizabeth George, Intan Nureslyna Samsudin, Lee Hoong Hong, Ling Ling Chuo, Nabilah Ramli, Muhd Zanapiah Zakaria

    The principal cause of iron overload in patients with haematological malignancies is recurrent red cell transfusions for anaemia. The serum ferritin level reflects the iron burden in the body, in the absence of inflammation or liver disease. In Malaysia, data are lacking on the association between pre-transplant serum ferritin levels and outcome after allogeneic haemopoietic stem cell transplant. We did a cross-sectional study using retrospective data of 106 post-allogeneic haemopoietic stem cell transplant patients (HLA-matched sibling) with haematological malignancies at Hospital Ampang to determine the relationship between pre-transplant serum ferritin levels and post-transplant outcome, post-transplant complications and survival time. Patients were divided into two groups according to the iron status: serum ferritin level >1000 μg/L (iron overload) and <1000 μg/L. The median age for patients was 30.5 (18-58) years. The median pre-transplantation serum ferritin level and the prevalence of pre-transplantation iron overload were 2423 (408.2-7664) μg/L and 87.5%, respectively. No significant association was found between iron status and demographic factors, type of haematological malignancy and post-transplant complications. Although insignificant, patients with iron overload had a shorter survival time (36 months) compared to those with no iron overload (40 months). There was also no significant association between the iron status and post-transplant outcome. Significant post-transplant complications associated with post-transplant outcome were the need for total parenteral nutrition (TPN) (p=0.014) and chronic graft-versus-host disease (GVHD) (p=0.008). Similarly, significant associations were found between age group (p=0.003), TPN (p=0.035) and chronic GVHD (p=0.012) with survival time using Kaplan-Meir analysis. However, after Cox regression, only age group was found to be significantly associated with survival time (p=0.014). Serum ferritin is an acute phase reactant and its levels increase in the presence of tissue necrosis and inflammation. Both these events occur in haematological malignancies. Although serum ferritin level is a non-invasive, relatively cost-effective, widely available and practical indicator of iron status, it is not specific to iron overload. Therefore, a true association between the serum ferritin level and iron burden is problematic in patients with haematological malignancies.